L & S Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

L & S Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,000	Closed	-$297K	–	387
2020 Q4	$297K	Buy	+10,000	New	+$254K	0.03%	279

Other funds holding RYTM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

L & S Advisors's RYTM Position: Q1 2021 in Review

L & S Advisors sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2021, closing a stake of 10,000 shares — an estimated $297K sold.

L & S Advisors first reported a position in RYTM in Q4 2020 and held it in 1 quarter. The position peaked at $297K in Q4 2020. 124 funds tracked by Wall St. Rank hold RYTM as of Q1 2021.

L & S Advisors reported no remaining Rhythm Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
L & S Advisors sold 10,000 Rhythm Pharmaceuticals shares in Q1 2021, an estimated $297K.
L & S Advisors first reported a position in Rhythm Pharmaceuticals in Q4 2020 and held it in 1 quarter.
L & S Advisors's Rhythm Pharmaceuticals position peaked at $297K in Q4 2020.
124 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2021.

Based on L & S Advisors's 13F filing for Q1 2021, filed 10 May 2021.